Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases  

作　　者：Yongmei Liu Jianhua Lu Haoting Zhan Wenfang Yuan Xiaomeng Li Haiyan Kang Haolong Li Yongliang Chen Linlin Cheng Xingli Sun Haojie Zheng Wei Wang Erhei Dai Yongzhe Li 

机构地区：[1]Department of Clinical Laboratory,State Key Laboratory of Complex,Severe and Rare Diseases,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing,100730,China [2]Division of Liver Diseases,The Fifth Hospital of Shijiazhuang,Hebei Medical University,Shijiazhuang,050021,China [3]Department of Clinical Laboratory,The Fifth Hospital of Shijiazhuang,Hebei Medical University,Shijiazhuang,050021,China [4]Department of Clinical Laboratory,Peking University People's Hospital,Beijing,100035,China

出　　处：《Virologica Sinica》2023年第5期723-734,共12页中国病毒学（英文版）

基　　金：This work was supported by the Beijing Natural Science Foundation(M23008);the National Key Research and Development Program of China(2018YFE0207300);Beijing Municipal Science&Technology Commission(Z211100002521021);the National High Level Hospital Clinical Research Funding(2022-PUMCH-B-124);Key Research and Development Plan of Hebei Province,Special Health Innovation Project(22377744D).

摘　　要：Chronic liver disease(CLD)entails elevated risk of COVID-19 severity and mortality.The effectiveness of the booster dose of inactivated SARS-CoV-2 vaccine in stimulating antibody response in CLD patients is unclear.Therefore,we conducted a cross-sectional study involving 237 adult CLD patients and 170 healthy controls(HC)to analyze neutralizing antibodies(NAbs)against SARS-CoV-2 prototype and BA.4/5 variant,anti-receptor binding domain(RBD)IgG,and total anti-SARS-CoV-2 antibodies.Serum levels of the total anti-SARS-CoV-2 antibodies,anti-RBD IgG and inhibition efficacy of NAbs were significantly elevated in CLD patients after the booster dose compared with the pre-booster dose,but were relatively lower than those of HCs.Induced humoral responses decreased over time after booster vaccination.The neutralization efficiency of the serum against BA.4/5 increased but remained below the inhibition threshold.All four SARS-CoV-2 antibodies,including total anti-SARS-CoV-2 antibodies,anti-RBD IgG and NAbs against prototype and BA.4/5,were lower in patients with severe CLD than those with non-severe CLD.After booster shot,age and time after the last vaccine were the risk factors for seropositivity of NAb against BA.4/5 in CLD patients.Additionally,white blood cell counts and hepatitis B core antibodies were the protective factors,and severe liver disease was the risk factor associated with seropositivity of total anti-SARS-CoV-2 antibodies.Overall,our data uncovered that antibody responses were improved in CLD patients and peaked at 120 days after the booster vaccines.All antibodies excepting total anti-SARS-CoV-2 antibodies declined after peak.CLD patients exhibited impaired immunologic responses to vaccination and weakened NAbs against BA.4/5,which hindered the protective effect of the booster shot against Omicron prevalence.Cellular immune responses should be further evaluated to determine the optimal vaccine regimen for CLD patients.

关 键 词：Chronic liver disease(CLD) SARS-CoV-2 inactivated vaccines Booster vaccination Antibody response Immune response 

分 类 号：R563.1[医药卫生—呼吸系统]